Ciamexon (Ciamexone) is a novel immunomodulator that has shown promising results in experimental models of autoimmune disease with little demonstrated cytotoxicity.Ciamexon can be used to study endocrine ophthalmopathies and diabetes mellitus, with slight improvement in ophthalmic disease following short-term administration.

Ac-VDID TFA is a short peptide sequence with Ac at the end.

BAPTA-AM 是一种选择性、膜渗透性钙螯合剂。